Is it working? Are your symptoms improving, staying the same, or getting worse? You may be asked to fill out a couple of ...

With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...

It can transition into chronic urticaria for up to 8% of the population. Hives tend to go away without treatment, but self-care strategies like taking a cooling bath can help manage discomfort. Some ...

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

Hives and eczema both involve itchy skin rashes and are related to allergies. While they may share some similarities, these two conditions are distinct in their symptoms, underlying causes, and ...

If you’ve ever experienced the itchiness, burning, or stinging sensations that hives can cause, you know that remedies that offer immediate relief are what you want. Hives — also known as ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The medical term for this is “chronic urticaria." When you have chronic hives, the most effective treatment often depends on the type of hives you have and your medical history. Make an appointment to ...

Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the EU based on earlier study readouts. Outside of Japan and the UAE, the safety ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.